Loading...
XNYS
RVTY
Market cap11bUSD
Dec 05, Last price  
100.79USD
1D
-1.72%
1Q
16.33%
Jan 2017
93.27%
Name

Perkinelmer Inc

Chart & Performance

D1W1MN
XNYS:RVTY chart
P/E
40.41
P/S
4.34
EPS
2.49
Div Yield, %
0.28%
Shrs. gr., 5y
1.95%
Rev. gr., 5y
-0.91%
Revenues
2.76b
+0.16%
1,473,831,0001,546,358,0001,787,331,0001,937,465,0001,812,202,0001,704,346,0001,921,287,0002,115,205,0002,166,232,0002,237,219,0002,262,359,0002,115,517,0002,256,982,0002,777,996,0002,883,673,0003,782,745,0005,067,169,0003,311,822,0002,750,571,0002,755,026,000
Net income
296m
-57.32%
66,532,000119,583,000131,686,000126,409,00085,599,000135,922,000174,00069,940,000167,212,000157,778,000212,425,000234,299,000156,890,000237,927,000227,558,000727,887,000943,157,000569,179,000693,094,000295,833,000
CFO
628m
+588.38%
208,093,000127,440,000205,127,000217,844,000148,722,000164,253,000224,874,000152,170,000158,591,000281,597,000287,098,000350,615,000288,453,000311,038,000363,469,000892,177,0001,410,750,000679,810,00091,272,000628,299,000
Dividend
Jan 16, 20260.07 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
IPO date
Jul 06, 1965
Employees
11,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT